Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,852
  • Shares Outstanding, K 10,306
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,080 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +17.00%
on 03/26/26
1.3200 -11.36%
on 03/18/26
-0.0600 (-4.88%)
since 03/16/26
3-Month
1.0000 +17.00%
on 03/26/26
1.4600 -19.86%
on 01/22/26
-0.2400 (-17.02%)
since 01/16/26
52-Week
1.0000 +17.00%
on 03/26/26
6.2299 -81.22%
on 08/18/25
-0.8900 (-43.20%)
since 04/16/25

Most Recent Stories

More News
Soligenix (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism...

SNGX : 1.1700 (+1.74%)
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA),...

AIDX : 1.7200 (-0.86%)
BKYI : 0.6455 (+6.33%)
SNGX : 1.1700 (+1.74%)
SOPA : 0.5520 (+2.99%)
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology...

SNGX : 1.1700 (+1.74%)
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor ® during 12-week treatment course

SNGX : 1.1700 (+1.74%)
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim...

SNGX : 1.1700 (+1.74%)
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trial

SNGX : 1.1700 (+1.74%)
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation from the...

SNGX : 1.1700 (+1.74%)
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J. , March 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.1700 (+1.74%)
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap...

SNGX : 1.1700 (+1.74%)
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop...

SNGX : 1.1700 (+1.74%)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 1.2400
2nd Resistance Point 1.2100
1st Resistance Point 1.1900
Last Price 1.1700
1st Support Level 1.1400
2nd Support Level 1.1100
3rd Support Level 1.0900

See More

52-Week High 6.2299
Fibonacci 61.8% 4.2321
Fibonacci 50% 3.6149
Fibonacci 38.2% 2.9978
Last Price 1.1700
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.